What Is Arcadia Biosciences, Inc. (RKDA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Arcadia Biosciences, Inc.'s intrinsic value is estimated at $1.45, suggesting a +118.7% average upside from the current price of $0.66. While 6 models see room for appreciation, model agreement is not unanimous as 3 models flag potential overvaluation. Model dispersion is worth noting: ML-RIV targets $3.79 (+473.4%), versus EPV at $0.34 (-47.9%). This +521.2% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About RKDA?
9 of 13 models are currently active for RKDA. Of these, 6 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates RKDA's intrinsic value at $0.41, implying -38.4% downside from the current price. See which stocks rank higher →
How Does RKDA Rank in Crude Petroleum & Natural Gas?
Among 80 Crude Petroleum & Natural Gas stocks, RKDA ranks #58 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.
See all Most Undervalued Crude Petroleum & Natural Gas Stocks →
The Crude Petroleum & Natural Gas sector introduces analytical considerations specific to energy producer businesses. For Arcadia Biosciences, Inc., metrics like debt-to-EBITDAX provide important context that general-purpose valuation models may underweight.
Is RKDA a Value Trap?
CirclFi's Value Trap algorithm assigns RKDA a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Arcadia Biosciences, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Arcadia Biosciences, Inc. scores 5.6 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +521.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every RKDA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across RKDA's 9 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad